Small Cap Feast
Small Cap Feast – 03 March 2017
Dish of the Day:
No AIM Joiners Today
No AIM Joiners Today
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
Kuwait Energy –Report in Bloomberg that the oil & gas exploration business is considering a London IPO with a valuation of up to $1bn.
BiopPharmma Credit—Targeting $300m + raise on LSE. “This investment trust will give investors access to debt investments tied to the fast growing life sciences industry, offering predictable cash flows over a sustained period of time.” Admission due 27 Mar.
Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.
Anglo African Oil & Gas— Schedule 1 update. Acquiring stake in producing near offshore field in the Republic of the Congo. Raising £10m. Admission due 6 March.
Venn Life Sciences* (VENN.L) 17.25p £10.39m
Year end update from the growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations.
2016 represented another year of strong growth for Venn with sales in excess of €18m (2015 €11m). The business finished 2016 with a strong cash position of €3m (€1.75m 30 June 2016). The strong momentum enjoyed by the business in 2016 has continued into 2017 to date, with new business contracts signed to the value €5.7m in the first two months of the year.
MediaZest* (MDZ.L) 0.12p £1.43m
New business update from the creative digital audio visual company. Since the start of 2017, the Group has already confirmed business wins in the retail sector alone that relate to projects that will generate approximately £500k of new revenue. These projects include the ongoing roll out of business from existing clients and a substantial new project for a UK high street bank. All are due for completion by 30 June 2017. Includes large proportion of UK work but also installations as far afield as the US and Australia. In addition, the Group continues to grow its recurring revenue base, which has underpinned recent improved results. At present, run rate recurring revenues total approximately £400,000 per annum and management expect these to grow by at least 15% during the next quarter.
Legendary Investments (LEG.L) 0.18p £5.05m
Investee company VS (Virtualstock Holdings), has been appointed by the John Lewis Partnership, which includes 48 John Lewis shops across the UK, johnlewis.com and 349 Waitrose shops, to implement its Supply Chain Management System, The Edge. As at 31 March Legendary’s 7% stake in VS was valued at £4m in the books.
‘Early last year, Virtualstock had three household retailers, Tesco, Sainsbury’s Argos and MapIin as clients. It now has more than double that number, including the John Lewis Partnership. Virtualstock is now established as a leading supply chain solution in retail, and it is in discussion with several additional retail clients. ‘ Last reported NAV £4.8m.
AFH Financial (AFH.L) 185p £44.75m
AGM statement from the financial planning led wealth management firm. The Company’s core business continues to perform in line expectations and that recurring revenue continues to remain strong as a result of the inflow of new funds during the period. As in 2016, gross margins remain above the 55% level. During the first four months of the current financial year the AFH announced 5 acquisitions, paying £2m in initial cash consideration. Whilst these acquisitions are not expected to make a material contribution to H1 the benefits arising from these businesses are expected to benefit earnings in the current year’ Strong pipeline of further acquisitions and £4.1m cash as at 1 March. FY Oct17E revenue of £28m and £4.46m PBT.
Intercede Group (IGP.L) 52p £25.8m
Trading update from the software and service company specialising in identity, credential management and secure mobility. Following the January announcement of the receipt of a record $3m order, the order book indicates that, unless further orders are received that can be recognised as revenue in this period, revenue for the FYMar2017 will be approximately £8.0m. A further £2.0m of new orders remain in the current period pipeline which includes US government and defence contractor customers. Timing risks mean FYMar17 losses may be higher than expectations. US defence spending proposals have caused short term uncertainty but positive for long term revenue potential. FYMar17E £10m rev and £2.67m pre-tax loss.
Gear4Music Holdings (G4M.L) 675p £136m
FY Feb 2017 trading update from the largest UK based online retailer of musical instruments and music equipment. 58% increase in total like-for-like sales following continued strong growth in the UK and Europe. 186% Scandinavian sales growth between November 2016 – when the Swedish Distribution Centre opened – and February 2017. German Distribution Centre now operational. Active customer numbers increased by 49% over the year to 339,800. Total revenue £56.1m. “Whilst continuing to invest in the future growth of the business, we have closely managed our costs and the Board is now confident of delivering profits for the year marginally ahead of our increased expectations signalled in January.” FYFeb17E rev of £56m and EPS of 2.39p.
Trakm8 Holdings (TRAK.L) 78.5p £25.48m
The telematics and data insight provider, announced that it proposes to raise approximately £1.66 million at 65p, a 17% discount to yesterday’s close. Includes c. £811,000 participation by eight Directors and senior managers of the Company demonstrating significant Company support. The net proceeds of the Capital Raising will both reduce the balance of the Group’s revolving cash facility with its bank and strengthen its working capital position to support future growth.
Kodal Minerals (KOD.L) 0.22p £11.35m
The mineral exploration and development company focussed on West Africa, is has updated on the recently completed trenching and the upcoming drilling campaign at the Bougouni Lithium Project in Southern Mali. New wide zones (>30m) of pegmatite veins with abundant spodumene mineralisation (the main lithium bearing mineral in most hard rock lithium deposits) defined by recently completed trenching programme. Reverse Circulation drilling to commence in early March 2017, initially targeting the Ngoualana prospect where previous drilling confirmed wide, high-grade mineralisation of up to 28m at 1.84% Li2O. Further follow up drilling planned. Seeking a maiden resource in 2017.
Applied Graphene Materials (AGM.L) 150p £33.2m
Period end (31 Jan 17) operational update from the provider of bespoke graphene dispersions and formats to deliver enhancements and benefits for a wide range of applications. Composites: Development of graphene enhanced pre-impregnated composites with SHD Composites. Collaboration with Century Fishing Rods leading to 1st production orders. Development of enhanced aerospace structures. Product development with Airbus Defence and Space. Coatings:· JDA with James Briggs Ltd. ISO testing results proving outstanding corrosion barrier properties. Oils and Lubricants: PURAGLOBE commenced test-marketing AGM graphene enhanced sustainable base oil technology .
Velocys (VLS.L) 60.87p £87.66m
The company at the forefront of smaller scale gas-to-liquids, has signed a definitive agreement covering its strategic alliance with Morimatsu (Jiangsu) Heavy Industry Co., Ltd., a subsidiary of Morimatsu Industry Co., Ltd. (Morimatsu). This agreement confirms the previously announced Memorandum of Understanding between Velocys and Morimatsu; Morimatsu will be Velocys’ preferred supplier of modular design, engineering and fabrication services supporting the Velocys offer of delivering fully integrated, fully financed, cost effective and operations-ready plants to its customers.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.